Clinical Trials Logo

Neuroendocrine Prostate Cancer clinical trials

View clinical trials related to Neuroendocrine Prostate Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT01799278 Completed - Clinical trials for Neuroendocrine Prostate Cancer

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

Start date: February 2013
Phase: Phase 2
Study type: Interventional

This study will evaluate the response rate of MLN8237 in patients with histologically confirmed or clinically suspected metastatic neuroendocrine prostate cancer (NEPC). MLN8237 is an orally administered Aurora kinase A inhibitor that has demonstrated broad antitumor activity in vitro and in vivo. In preclinical models, aurora kinase inhibition resulted in dramatic and preferential anti-tumor activity in NEPC with suppression of neuroendocrine marker expression.